Type II secretory phospholipase A 2 (sPLA 2 -IIA) is widely expressed in various cell types and may trigger local inflammatory responses. We sought to evaluate whether systemic sPLA 2 is associated with prognosis in patients with coronary heart disease (CHD).
Introduction
Type IIA secretory phospholipase A 2 (sPLA 2 -IIA) is a well-studied member of the phospholipase A 2 family and is widely expressed in hepatocytes, macrophages, platelets, and vascular smooth muscle cells. 1 Type IIA secretory phospholipase A 2 is a Ca 2þ -dependent, 14 kDa enzyme which belongs to the group of acute phase reactants. Production of sPLA 2 -IIA is up-regulated in response to pro-inflammatory compounds such as interleukin (IL)-1b, IL-6, tumour necrosis factor-a, interferon-g, and oxidized low-density lipoprotein (LDL).
1,2
The catalytic function of this enzyme is related to the hydrolysis of the sn-2 acyl group of glycerophospholipids with further liberation of fatty acids and lysophospholipids, all playing an important role in the biosynthesis of lipid mediators such as PAF, leukotrienes, prostaglandins, and eicosanoids. 3, 4 However, in contrast to lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ), sPLA 2 -II can also hydrolyse unmodified phospholipids. In addition, an anti-bacterial role of sPLA 2 , due to degradation of phospholipids in the lipid membrane of gram-positive infectious agents, is also possible. 5, 6 Possible atherogenic mechanisms of sPLA 2 -IIA include its effects on lipoproteins which results in the release of various lipid mediators at the site of lipoprotein retention in the arterial wall that in turn may trigger local inflammatory cellular responses. 1 Furthermore, in arterial tissue, sPLA 2 -IIA may also directly modify LDL particles to become more atherogenic and may increase the affinity of ApoB-100 on LDL to glycosaminoglycans and proteoglycans. 1, 7 Type IIA secretory phospholipase A 2 is also implicated in the production of isoprostanes which exhibit strong mitogenic activity and induce platelet aggregation and vasoconstriction. 1 In vivo studies of transgenic mice overexpressing human sPLA 2 -IIA showed an enhanced formation of bioactive oxidized phospholipids, as well as an increased formation of atherosclerotic lesions. 1, 8 The involvement of sPLA2-IIA in various atherogenic mechanisms would make sPLA2-IIA a promising treatment target in patients with atherosclerosis. To date only few studies have prospectively examined the potential value of sPLA 2 -IIA mass and activity to predict future risk from cardiovascular diseases (CVD), 9 -14 and only rarely were able to consider both measures simultaneously. Thus, since there is little data in patients with stable coronary heart disease (CHD), we investigated the risk of recurrent cardiovascular events associated with sPLA 2 -IIA levels in a large cohort of patients with manifest CHD. Furthermore, we wanted to examine its prognostic value after considering other emerging risk markers, such as C-reactive protein, cystatin C as an indicator of renal function, and N-terminal-probrain natriuretic peptide (NT-proBNP) as a measure of haemodynamic stress.
Methods

Study population
All patients with CHD (International Classification of Diseases, 9th Rev. codes. 410 -414) aged 30 -70 years and participating in an in-hospital rehabilitation program between January 1999 and May 2000 in two cooperating hospitals (Schwabenland-Klinik, Isny and Klinik im Südpark, Bad Nauheim, Germany) were enrolled in the study. In Germany, all patients after an acute coronary syndrome (ACS) or elective coronary artery bypass grafting (CABG) are offered a comprehensive in-hospital rehabilitation program after discharge from the acute care hospital. The aim of this 3-week program is the reduction of cardiovascular risk factors, improvement of health related quality of life, and the preservation of the ability to work (the latter only if a subject was still at work at the onset of disease, otherwise the prevention of nursing care). This in-hospital rehabilitation program usually starts 3 weeks after the acute event or CABG. In the current study, only patients who were admitted within 3 months after the acute event or CABG were included.
All subjects gave written informed consent. The study was approved by the Ethics Boards of the Universities of Ulm and Heidelberg and of the Physicians' chamber of the States of Baden-Wuerttemberg and Hessen (Germany).
Data collection
At the beginning of the in-hospital rehabilitation program, all subjects filled out a standardized questionnaire containing socio-demographic information and medical history. In addition, information was taken from the patients' hospital charts. In all patients, active follow-up was conducted 1, 3 and 4.5 years after discharge from the rehabilitation centre. Information was obtained from the patients using a mailed standardized questionnaire. Information regarding secondary CVD events and treatment since discharge from the in-hospital rehabilitation clinic was obtained from the primary care physicians also by means of a standardized questionnaire. If a subject had died during follow-up, the death certificate was obtained from the local Public Health Department and the main cause of death was coded according to the International Classification of Diseases (ninth Revision). Secondary CVD events were defined either as CVD as the main cause of death (as stated in the death certificate), non-fatal myocardial infarction (MI), or non-fatal stroke. All non-fatal secondary events were reported by the primary care physicians. The last follow-up information was obtained 21 June 2005.
The total response during baseline recruitment was 58%, resulting in the total number of 1206 patients included in the study at baseline. Follow-up information was complete for 1051 patients (87.2%). We could perform serum measurements on sPLA2 mass and activity only for 1024 patients (97.4% of the overall population with complete follow-up information) due to limited serum in some of the participants. From the other variables of interest, we had very few missing values [high-density lipoprotein (HDL)-cholesterol (n ¼ 5), LDL-cholesterol (n ¼ 13), and triglycerides (n ¼ 1)]. We replaced missing values by the mean of the population sample in the multivariable analyses.
Laboratory methods
Blood at baseline was drawn at discharge from the rehabilitation centre (on average 43 days after the acute event; first quartile 36 days, third quartile 51 days) in a fasting state under standardized conditions and stored at 2808C until analysis. Serum concentrations of sPLA 2 were determined by a commercially available sPLA 2 -IIA -ELISA kit (Cayman Chemical Co., Ann Arbor, MI, USA). The lower detection limit of sPLA 2 -IIA in this assay is 0.3 ng/mL. The inter-assay coefficient of variation (CV) was 16.5%. Serum sPLA 2 activity was measured by a selective fluorometric assay by using fluorescent substrate 1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3 phosphomethanol, sodium salt (Interchim, Montlucon, France), as previously described. 10 C-reactive protein concentrations were measured by immunonephelometry on a Behring Nephelometer II (N Latex C-reactive protein mono Dade-Behring, Marburg). Cystatin C was determined on the same device 15 
Statistical methods
The study population was described with respect to various sociodemographic and medical characteristics. The associations of sociodemographic characteristics, various cardiovascular risk factors, and medication with sPLA 2 -IIA concentrations were quantified by means of the non-parametric Kruskal -Wallis test. Partial Spearman correlation coefficients, adjusted for age and gender, were calculated for sPLA 2 and prognosis in CHD sPLA 2 -IIA concentrations and blood lipids, C-reactive protein, creatinine clearance, cystatin C, NT-proBNP, and Lp-PLA 2 .
The relation of sPLA 2 -IIA concentrations with CVD events during follow-up was assessed by the Kaplan -Meier and life table method and quantified by means of the log-rank test. Then the Coxproportional hazards model was employed to assess the independent association of sPLA 2 -IIA concentration with the risk of secondary CVD events (hazard ratios, HR, and their 95% confidence intervals, CI). The goal of our modelling strategy was to get an unbiased estimate of the risk of recurrent cardiovascular events associated with sPLA 2 -IIA levels after adjustment for established risk factors. The proportional hazards assumption was assessed graphically and based on the multivariable model (second column in Table 4 ). A basic model was adjusted for age (years) and gender. In a second step, beside the main factor sPLA 2 -IIA and the variables age, gender, and hospital site, the following established confounders were included in multivariable analyses: body mass index (BMI, kg/m 2 ), smoking status (never, current, ex-smoker), history of hypertension (yes, no), history of diabetes mellitus (yes, no), number of affected vessels (one, two, three), initial management of CHD [conservative, percutaneous coronary intervention (PCI), CABG], HDL-cholesterol (mg/dL), LDL-cholesterol (mg/dL), treatment with lipid lowering drugs. In the last two steps, adjustment for Creactive protein (mg/L), cystatin C (mg/L), and NT-proBNP (ng/mL) was done, and finally Lp-PLA 2 mass (ng/mL) was adjusted for.
Significance tests were two-tailed, and P-values less than 0.05 were considered as statistically significant. All statistical procedures were carried out with the SAS statistical software package (release 8.2, Cary, NC, USA, SAS Institute Inc. 1999). Table 1 shows the main sociodemographic, and laboratory characteristics in the 1024 patients with clinically manifest CHD. The mean age of CHD patients was 59 years, of them, 84% were men. Main laboratory characteristics are further displayed in this table. Mean LDL-C was remarkably low with 100.9 mg/dL (SD 29.4). Table 2 shows the distribution of sPLA 2 -IIA mass and activity according to various factors and indicates that sPLA 2 -IIA mass and activity values differ between genders, are age-dependent, higher in diabetic and hypertensive patients and those with advanced CHD, as well as in those after CABG ( Table 2) . Table 3 shows partial Spearman rank correlation coefficients between sPLA 2 -IIA mass and activity and various other biomarkers. Type IIA secretory phospholipase A 2 mass and activity were positively correlated with leucocyte count, C-reactive protein, cystatin C, NT-proBNP, and Lp-PLA 2 mass and activity (all P-values were statistically significant). Type IIA secretory phospholipase A 2 activity was also strongly correlated with mass (R ¼ 0.63, P , 0.0001) ( Table 3) .
Results
During a median follow-up of 4.6 years (interquartile range: 4.4 -4.7), 93 patients experienced a secondary CVD event (29 cardiovascular deaths, 35 non-fatal MIs, and 29 non-fatal strokes). Figures 1 and 2 show Kaplan -Meier curves, presenting the incidence of those with secondary CVD events per 1000 patient years according to tertiles of sPLA 2 -IIA mass and activity at baseline. Of patients in the bottom tertile of sPLA 2 mass and activity, 13.9 and 16.0, respectively, per 1000 patient years experienced an event compared with 28.3 and 29.1 per 1000 patient years for mass and activity, respectively, in the top tertile (P ¼ 0.02 and 0.07, respectively). Table 4 shows the association of sPLA 2 -IIA mass and activity with the composite endpoint after adjustment for various confounders. In a multivariable model, that included besides age, gender and hospital site also smoking status, history of diabetes, initial management of CHD, as well as LDL-C, HDL-C, and treatment with lipid lowering drugs (of whom more than 90% were statins), sPLA 2 -IIA mass and activity in the top tertile showed HRs of 2.07 (95% CI, 1.17 -3.66) and with 1.65 (95% CI, 0.96 -2.84), respectively, compared with the bottom tertile. After adjustment for other emerging and established biomarkers of subsequent CVD risk such as C-reactive protein, cystatin C, and NT-pro-BNP, the HRs decreased to 1.80 (95% CI, 0.98-3.29) and 1.48 (95% CI, 0.84-2.62). Subsequently, including Lp-PLA 2 mass in the model, HRs were further attenuated the HRs.
Analysing sPLA 2 -IIA mass and activity as continuous variables resulted in only minor changes of risk estimates across all models which remained statistically significant for both variables in the final model and when including quadratic terms to the model we found no evidence of additional non-linear components. Although sPLA2 mass and activity were associated with the secondary CVD events, their inclusion in the basic model ( Table 4 , column 2) did only marginally increase the area under the receiver operating characteristic curve from 0.695 to 0.696 (for mass) and to 0.700 (for activity) (both increases were not statistically significant). 
Discussion
In this large, well-characterized cohort of patients with manifest CHD, followed for 4 years we found that a single measurement of sPLA 2 -IIA mass and activity at baseline were associated with recurrent events, even after controlling for both established and emerging risk factors that meanwhile have been suggested as strong markers for subsequent CVD events. Looking at the top tertiles, there was an 80% increased risk for CVD events for sPLA 2 -IIA mass and a 50% increased risk for activity. Most notably, in analyses that used sPLA 2 -IIA as a continuous variable, a statistically significant increased risk associated in either mass or activity was seen in all models, that even persisted in the models containing both measures. Although sPLA 2 mass and activity were strongly correlated, the association of mass with secondary CVD events seemed stronger.
Associations of secretory phospholipase A 2 with other risk markers
As an acute phase reactant, sPLA 2 -IIA mass and activity were moderately but highly significantly correlated with other markers of inflammation. Correlations were somewhat stronger with C-reactive protein compared with leucocyte count but in the same magnitudes as has been reported in the literature. 11, 14 In addition, mass and activity were also correlated with cystatin C, a sensitive indicator of renal function but not with creatinine clearance. This may either be due to the superior performance of cystatin as a marker of glomerular filtration or cystatin C reflects other properties that have not been investigated in detail so far. Furthermore, again both mass and activity correlated with NT-proBNP, a marker of haemodynamic stress which has also been reported for other markers of the acute phase. Of note, all correlations reported were stronger for mass than for activity except for the correlation with Lp-PLA 2 mass and activity. Finally, sPLA 2 mass and activity in our study were strongly correlated (r ¼ 0.63), whereas in the study by Mallat et al., 13 the correlation was only r ¼ 0.37. Thus, different activity assays have to be considered as their results may vary.
Secretory phospholipase A 2 measurements and prediction of cardiovascular events
Elevated sPLA 2 -IIA mass and increased activity have both been demonstrated to predict coronary events in healthy subjects. In two nested case-control studies from the EPIC Norfolk study comprising, respectively, 3314 and 2797 subjects, 10 elevated levels of sPLA 2 -IIA were associated in the first study with a 34% increased risk for future CHD events in multivariable analyses across extreme quartiles [odds ratio (OR) 1.3; 95% CI 1.0-1.7] compared with a much stronger 189% increased risk seen with increased activity (OR 2.89, 95% CI 1.78 -4.68). On the basis of these different results, the authors concluded that sPLA 2 activity, which encompasses several types of sPLA 2 including type IIA, V, and X may better reflect the causative role of sPLA 2 in the atherogenetic process. 10 However, results in these healthy subjects that came from the same study population have to be corroborated by others until the clinical usefulness of sPLA 2 -IIA in the prediction of CHD in the primary care setting may be established. In a small study of 52 patients with unstable angina, 107 stable CHD patients and 96 controls 12 sPLA 2 levels were measured and follow-up was done in the unstable angina group over a 2-year period. First, levels were found to be higher in unstable patients compared with stable patients and controls. Secondly, in multivariable models, ORs for a coronary event varied between 3.0 (95% CI 1.2 -7.4) and 5.1 (95% CI 1.4 -18.6) depending upon the underlying coronary anatomy and whether or not patients had suffered a previous MI. The very large CIs reflect the extremely small numbers in the various subgroups studied. Mallat et al. 13 studied 446 patients with severe ACS from the Global Registry of Acute Coronary Events and followed them for a median of 5.6 months. At enrolment several biomarkers were measured including sPLA 2 activity and antigen. In multivariable analysis, only sPLA 2 activity but not antigen was strongly associated with the composite endpoint of death or MI (HR 3.08; 95% CI 1.37-6.91). Elevated plasma levels of sPLA 2 were significant and independent predictors of future cardiovascular events in a small study with 142 CHD patients, 76% of them in stable conditions, and 93 controls during a 2-year follow-up. 11 In multivariable analysis, the OR for a future event for those in the top tertile was 3.46 (95% CI 1.4 -8.3) compared with those in the bottom tertile. Finally, in a study with 247 consecutive CHD patients undergoing PCI and 100 controls increased sPLA 2 measured after the intervention independently predicted outcome after 2 years (OR 2.1; 95% CI 1.4 -7.0). Taken together, six studies so far have reported on sPLA 2 mass and/or activity as a predictor of future CVD events. However, except for the two reports form EPIC Norfolk, the cohorts are fairly small and heterogeneous. This may explain the somewhat high risk estimates seen in most of them. Also, different assays have been used which might not be strictly comparable between sPLA 2 and prognosis in CHD studies. It is difficult to explain the discrepant results in some studies concerning activity and mass. 10, 13 Thus, larger studies in diverse populations are certainly needed using assays with high precision and an established standard so that results may be compared among studies. Nevertheless, sPLA 2 -IIA seems to be an interesting biomarker candidate and treatment target since already an inhibitor exists.
Study strengths and limitations
To the best of our knowledge, this study represents the largest population of patients with stable disease in whom blood was taken 3 months after the acute events (and thus an acute phase effect can be excluded) and follow-up was longer than in all other studies investigating CHD patients. However, our study has several limitations which should be considered. Although we had a large sample of patients with CHD (over 50% with a history of MI), fatal CVD events were limited in this study population. This is explained by the fact that mortality of MI is highest during the pre-and early in-hospital phase. As the acute events leading to diagnosis of CHD or MI had occurred at least 3 weeks before inclusion in this study, selection of patients with a better prognosis compared with a patient population within the early phase of a newly diagnosed CHD must be assumed. Furthermore, not all patients were willing or able to participate in an in-hospital rehabilitation program. This may be a further reason for the underrepresentation of severely ill patients in our study sample. However, this does not explain the positive findings between sPLA 2 and CVD events, but suggests that the true prognostic value of sPLA 2 may even be stronger than shown in our study.
On the basis of generally accepted modelling constraints, ideally only one covariate should be included per 10 outcomes. When looking on the results of Table 4 , the second model from left should be considered the main model. However, when adding additional emerging biomarkers to this model, we decided not to reduce the number of variables to assure comparability of the various models. Finally, all non-fatal secondary events were reported by the primary care physicians and were based on established diagnoses in the charts of the patients. However, non-fatal CVD events were not further validated by additional enquiries.
Conclusions
In this setting of patients with manifest CHD, most after ACS, elevated concentrations of sPLA 2 -IIA mass and activity showed a statistically significant increased risk for secondary CVD events independent of a variety of potential confounders including markers of inflammation, renal function, and haemodynamic stress and even if considered simultaneously. If future clinical studies can strengthen the evidence in favour of an additional predictive role of sPLA 2 -IIA, this marker might represent an interesting target to further reduce residual risk for future CVD events in selected patient groups since a specific inhibitor is already available.
